BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
A Manual for Extravagant Vehicles Available in 2024 - 2Check out the exclusive pitch deck Valerie Health used to raise $30 million from Redpoint Ventures to automate healthcare faxes
- 3Netanyahu leads meeting on West Bank riots, Katz defends axing administrative detention for Jews
- 4Watch China's Shenzhou 22 rescue ship arrive at Tiangong space station (video)
- 5Living Abroad: Social Inundation and Self-improvement
- Overlooked infertility care should be part of national health services, says WHO
- Grasping the Commencement of Criminal Cases: An Extensive Outline
- 7 Strange Devices to Make Your Party Stick Out!
- Pick Your Favored method of transportation
- Explainer-What has happened to the damaged spacecraft at China's space station?
- 6 Web-based Course Stages for Successful Learning and Educating
- New research reveals urban raccoons across the US show early signs of domestication
- Find the Force of The ability to understand anyone on a deeper level: Improving Mindfulness and Connections
- 4 Dazzling And Well known Island Objections In US
